Legislation co-sponsored in the USA by Representatives Brian Bilbray (Republican, California), Carolyn Maloney (Democrat, New York) and Rosa DeLauro (Democrat, Connecticut), and supported by the Melanoma Research Foundation, seeks to encourage the development of so-called “significant drug combinations” by offering the carrot of an extension of marketing exclusivity.
HR 6502, the Life-Threatening Diseases Compassion through Combination Therapy Act of 2012, was recently introduced and appears to be modeled after the Generating Antibiotic Incentives Now Act (GAIN Act), which was enacted under Title VIII of the FDA Safety and Innovation Act (FDASIA), notes Kurt Karst, writing on the Hyman, Phelps & McNamara FDA Law Blog.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze